Lesson
Build the Autoimmune Exocrinopathy
Sjogren disease is not a dehydration disorder. Immune mediated gland dysfunction creates dry eye and dry mouth, while B cell activation and systemic inflammation can affect nerves, lungs, kidneys, blood vessels, joints, and hematologic tissues.
- Lacrimal gland
- Salivary gland
- Anti-SSA
- B cell activation
- Primary and associated disease
Immune activity reduces lacrimal and salivary function and damages protective surfaces.
Anti-SSA, biopsy, and objective gland tests support classification but do not replace diagnosis.
Nerves, lungs, kidneys, vessels, joints, and blood can become clinically important targets.
Start with exocrine function
Lacrimal glands sustain the tear film, while major and minor salivary glands lubricate the mouth, protect enamel, buffer acids, support swallowing, and limit infection. Loss of output creates tissue injury as well as discomfort.
Build the immune model
T cells, B cells, autoantibodies, cytokine signaling, epithelial activation, and focal lymphocytic inflammation contribute to disease. Anti-SSA supports classification and pregnancy risk assessment, but no antibody result replaces the clinical phenotype. Isolated anti-SSB does not contribute points to the 2016 classification score and is not independently diagnostic.
Use current terminology
Many current sources use Sjogren disease to emphasize a systemic disorder. It can occur without another autoimmune disease or in association with conditions such as rheumatoid arthritis or systemic lupus erythematosus.
Protect seronegative disease
A negative standard antibody panel does not settle every case. Objective ocular, salivary, pathologic, and systemic findings remain important when clinical probability is high.
Separate cause from consequence
Dryness can also result from anticholinergic medicines, dehydration, diabetes, radiation, infection, environmental exposure, aging, and other diseases. A rigorous evaluation identifies mimics and complications before assigning cause.
Quick check
Checking for saved practice…
Lesson
Recognize the Full Clinical Spectrum
Persistent dry eye and dry mouth are central, but a complete assessment also looks for functional loss, tissue damage, systemic activity, and findings that cannot safely wait for routine follow-up.
- Keratoconjunctivitis sicca
- Xerostomia
- Fatigue
- Extraglandular disease
- Urgent red flags
Vision, speech, swallowing, sleep, nutrition, and dental health reveal the real cost of dryness.
Raynaud, purpura, neuropathy, dyspnea, renal loss, cytopenia, and gland swelling change the plan.
Eye pain, vision loss, progressive weakness, persistent gland enlargement, and B symptoms cannot wait.
Characterize ocular symptoms
Grittiness, burning, photophobia, fluctuating vision, contact lens intolerance, and reflex tearing can accompany aqueous deficiency. Eye pain, reduced vision, focal epithelial injury, or ulceration requires urgent ophthalmic evaluation.
Characterize oral symptoms
Patients may carry water, wake to drink, struggle with dry food, speak for shorter periods, lose taste, develop oral burning, or experience recurrent caries and candidiasis. Ask how symptoms change nutrition and medicine administration.
Search beyond the glands
Inflammatory joint symptoms, Raynaud phenomenon, purpura, neuropathy, interstitial lung disease, renal tubular disease, cytopenias, thyroid disease, lymphadenopathy, and salivary gland enlargement can occur.
Interpret fatigue carefully
Fatigue can reflect inflammatory disease, pain, poor sleep, depression, anemia, thyroid dysfunction, medicine burden, or another disorder. It deserves a differential diagnosis rather than automatic immunosuppression.
Name urgent findings
Severe eye pain or vision change, inability to maintain intake, rapidly progressive weakness, dyspnea, purpura, persistent gland swelling, unexplained fever, drenching night sweats, and substantial weight loss require prompt escalation.
Quick check
Checking for saved practice…
Lesson
Use Objective Tests Without Confusing Their Roles
The 2016 ACR EULAR criteria use five weighted objective findings. They improve consistency for research and support clinical reasoning, but a classification threshold is not a substitute for diagnosis or a reason to ignore early disease.
- Anti-SSA
- Labial biopsy
- Ocular staining
- Schirmer test
- Unstimulated salivary flow
Either finding carries the greatest weight in the 2016 ACR EULAR score.
Ocular staining, Schirmer testing, and unstimulated saliva each add one when abnormal.
A score of at least four classifies an eligible patient, but early disease still requires longitudinal judgment.
Calculate the score
Anti-SSA positivity and focal lymphocytic sialadenitis on labial biopsy with at least one focus per 4 square millimeters each contribute three points. Ocular staining score at least five or van Bijsterveld score at least four in either eye contributes one point. Schirmer at most five millimeters in five minutes in either eye and unstimulated whole saliva flow at most 0.1 milliliters per minute each add one. At least four points classify an eligible patient; bilateral abnormal results do not double the eye-test points.
Check applicability
The criteria apply to patients with compatible dryness or systemic suspicion after relevant exclusions are considered. Head and neck radiation, active hepatitis C confirmed by PCR, AIDS, sarcoidosis, amyloidosis, graft versus host disease, and IgG4 related disease can interfere with classification.
Distinguish classification from diagnosis
Classification criteria were designed to standardize research populations. A clinician may continue evaluation when probability remains high despite a score below four, especially early in disease.
Use each test for its question
Schirmer testing measures tear production, ocular staining measures surface injury, salivary flow measures gland output, serology identifies immune markers, and labial biopsy can demonstrate focal inflammation. None answers every question alone.
Review reversible interference
Arrange a clinically appropriate interval off anticholinergic medicines before measuring objective eye and salivary dryness, coordinating any hold with the prescriber. Document interference when a hold is unsafe; do not ask patients to stop essential medicines themselves. Biopsy interpretation requires experienced pathology because focus score and tissue quality matter.
Quick check
Checking for saved practice…
Lesson
Protect the Ocular Surface From the First Visit
Dry eye care begins with mechanism, severity, and tissue protection. Aqueous deficiency can coexist with meibomian gland dysfunction, so lubrication alone is not always a complete plan.
- Aqueous deficiency
- Meibomian gland dysfunction
- Preservative free tears
- Ointment
- Punctal occlusion
Frequent use favors preservative free tears, while gels and ointments extend nighttime protection.
Aqueous deficiency and meibomian dysfunction may require different but coordinated measures.
Pain, photophobia, reduced vision, epithelial defect, or ulceration needs urgent ophthalmic care.
Reduce avoidable exposure
Review airflow, smoke, low humidity, prolonged screen use, incomplete blinking, contact lenses, and medicines that worsen dryness. Environmental changes support therapy but do not replace treatment of active surface disease.
Choose lubrication deliberately
Artificial tears are foundational. Preservative free products are preferred when drops are used frequently or preservatives cause irritation. Gels and ointments last longer and are often useful at night but can blur vision.
Treat mixed mechanism disease
Warm compresses, lid hygiene, and targeted management of meibomian gland dysfunction may be needed when evaporative disease accompanies aqueous deficiency.
Conserve tears selectively
Punctal occlusion can retain tears in selected patients. Surface inflammation, infection, tear composition, and the broader treatment plan should be assessed before plugs or cautery are used.
Escalate before sight is threatened
Persistent pain, photophobia, reduced vision, epithelial defect, or corneal ulceration warrants urgent examination. Severe disease may require autologous serum, scleral lenses, or other specialist procedures.
Quick check
Checking for saved practice…
Lesson
Treat Ocular Inflammation on the Correct Timeline
Topical cyclosporine and lifitegrast address inflammatory dry eye rather than providing immediate lubrication. Their value depends on regular use, correct technique, realistic timelines, and severity based ophthalmic follow-up.
- Cyclosporine
- Lifitegrast
- LFA-1
- Delayed benefit
- Advanced therapy
Delayed benefit and local burning require realistic counseling and sustained use when tolerated.
Twice daily dosing, lens separation, dysgeusia, and single dose technique shape safe use.
Punctal care, serum tears, scleral lenses, and supervised steroids require specialist selection.
Use topical cyclosporine
Cyclosporine reduces ocular surface inflammation and can support tear production in selected patients. Burning can occur, and meaningful benefit may take weeks to months. Some emulsions require gentle inversion before use according to product instructions.
Distinguish cyclosporine products
Restasis is a 0.05% emulsion; Cequa is a 0.09% solution. Both use one drop in each eye twice daily, about 12 hours apart. Restasis single-use vials require inversion to make the emulsion uniform; do not transfer that emulsion instruction to Cequa. Verify the actual product and device rather than treating all ocular cyclosporine as interchangeable.
Separate drops, lenses and containers
For Restasis single-use vials and Cequa, allow 15 minutes between the medicine and artificial tears. Remove contact lenses before dosing and wait 15 minutes before reinsertion if lens wear is appropriate. Avoid tip contact and discard the opened single-use vial after the dose; these instructions do not describe a multidose bottle.
Use lifitegrast
Lifitegrast is an LFA-1 antagonist labeled for signs and symptoms of dry eye. Instill one drop in each eye twice daily about 12 hours apart. Irritation, dysgeusia, and transient visual effects are important counseling points.
Teach device and lens technique
Single dose containers are discarded after use. Contact lenses are removed before lifitegrast and may be reinserted after 15 minutes. Avoid touching the container tip to the eye or another surface.
Store lifitegrast and recognize allergy
Keep unopened single-use containers in the original foil pouch until needed, protected from light. One opened container can dose both eyes once; discard the remainder. Altered taste is common, but wheezing, breathing difficulty or tongue swelling requires immediate medical care because serious hypersensitivity has been reported.
Use corticosteroids narrowly
A short topical corticosteroid course can be useful in selected inflammatory flares, but intraocular pressure, cataract, infection, and corneal risks require eye specialist supervision. It is not an indefinite self-directed treatment.
Match advanced care to severity
Punctal procedures, autologous serum tears, scleral lenses, amniotic membrane, and other interventions are considered when optimized topical therapy does not adequately protect the ocular surface.
Quick check
Checking for saved practice…
Lesson
Preserve Teeth, Mucosa, Swallowing, and Nutrition
Saliva protects much more than comfort. A prevention plan begins before the first cavity and integrates fluoride, dental surveillance, salivary support, infection recognition, diet, and medicine review.
- Topical fluoride
- Xylitol
- Saliva substitutes
- Candidiasis
- Dental prevention
Strong prevention begins before the first cavity and continues with structured dental care.
Water, xylitol, substitutes, and humidification avoid the sugar and acid costs of unsafe strategies.
Caries, erosion, candidiasis, mucosal injury, dysphagia, and poor intake require active care.
Make fluoride foundational
The Sjogren's Foundation strongly recommends topical fluoride for patients with dry mouth. Dental professionals individualize formulation and frequency from caries risk, dentition, and tolerance.
Use antimicrobial and remineralizing adjuncts selectively
A dental professional may consider chlorhexidine varnish, gel or rinse when dry mouth accompanies a high root-caries rate; the supporting recommendation is weak. Non-fluoride remineralizing products may supplement prevention in selected high-risk patients. Neither replaces fluoride, and Sjogren disease alone does not make indefinite daily antimicrobial mouthwash mandatory.
Match oral support to gland function
Assess salivary output before choosing therapy. EULAR favors non-drug stimulation for mild dysfunction, a monitored secretagogue trial for moderate dysfunction, and saliva substitutes when little or no usable gland function remains. Persistent symptoms are not a reason to keep escalating stimulation of a nonfunctioning gland.
Stimulate safely
Frequent water, sugar free xylitol gum or lozenges, saliva substitutes, and humidification can reduce burden. Avoid using frequent sugar or acidic candy as a salivary strategy because it can accelerate caries and erosion.
Review medicines and products
Anticholinergic medicines, sedating antihistamines, some antidepressants, bladder medicines, tobacco, alcohol, and alcohol containing mouth products can worsen dryness or oral injury. Modify therapy only through coordinated risk benefit decisions.
Look for complications
Inspect for caries, erosion, cracked mucosa, ulcers, denture injury, candidiasis, altered taste, and swallowing difficulty. Oral burning or plaques should not automatically be labeled autoimmune.
Protect intake and administration
Difficulty swallowing dry food can reduce nutrition and adherence. Use moisture, texture modification, dietitian support, and dosage form review rather than crushing medicines without checking whether the formulation permits it.
Quick check
Checking for saved practice…
Lesson
Use Systemic Secretagogues as Measured Therapeutic Trials
Pilocarpine and cevimeline can increase exocrine secretion when residual gland function remains, but their systemic muscarinic effects require cardiopulmonary, ocular, gastrointestinal, and medication review.
- Muscarinic agonism
- Pilocarpine
- Cevimeline
- Sweating
- Bronchospasm
The usual Sjogren dose is 5 mg four times daily; liver impairment can change the plan.
Thirty milligrams three times daily can improve saliva with a distinct schedule and tolerability profile.
Sweating, gut effects, breathing, vision, heart rate, and hydration define the usable trial.
Use pilocarpine precisely
Current labeling recommends pilocarpine 5 mg by mouth four times daily for Sjogren related dry mouth. Sweating, flushing, urinary frequency, nausea, diarrhea, dizziness, visual change, bradycardia, and bronchial effects can occur.
Distinguish guideline titration from the US label
BSR recommends a tolerability-led trial starting at 5 mg once daily and gradually increasing toward three or four daily doses when residual gland function is present. This is a guideline initiation strategy, distinct from the US labeled Sjogren schedule; the clinician chooses the plan and accounts for liver function.
Adjust pilocarpine for liver impairment
For moderate hepatic impairment, the US label starts pilocarpine at 5 mg twice daily, then adjusts to response and tolerability. Mild impairment does not require a reduction; use in severe impairment is not recommended. Do not copy the head-and-neck radiotherapy starting schedule into Sjogren treatment.
Use cevimeline precisely
Cevimeline is labeled at 30 mg by mouth three times daily for Sjogren related dry mouth. It can increase salivation but also sweating, gastrointestinal effects, secretions, airway resistance, heart rate or conduction effects, and miosis.
Check cevimeline exposure and interactions
Doses above 30 mg three times daily lack adequate evidence for additional benefit or safety. CYP2D6 and CYP3A4 inhibitors may raise exposure; reduced CYP2D6 activity also warrants caution. Renal and hepatic effects on its pharmacokinetics have not been established, so do not invent a fixed adjustment from the pilocarpine label.
Connect chemistry to product identity
Pilocarpine is a plant-derived imidazole alkaloid, while cevimeline is a structurally distinct synthetic muscarinic agonist. Studies of pilocarpine ophthalmic formulations documented hydrolysis to pilocarpic acid and epimerization to isopilocarpine. These formulation-specific observations do not establish an oral-tablet storage rule or a conversion dose between secretagogues. Current product labeling, not structure alone, governs dosing and handling.
Respect contraindications
Cevimeline is contraindicated in uncontrolled asthma, known hypersensitivity, and when miosis is undesirable, including acute iritis and angle closure glaucoma. Pilocarpine is likewise contraindicated in uncontrolled asthma, known hypersensitivity, and conditions where miosis is undesirable, including acute iritis and narrow-angle glaucoma.
Use caution beyond the label headline
Significant cardiovascular disease, controlled pulmonary disease, gallbladder or biliary disease, kidney stones, and medicines that alter cholinergic function or heart rate may require closer review.
Make safety advice actionable
Both secretagogues require review of beta blockers, additive cholinergic medicines and opposing antimuscarinics. Report heavy sweating with inadequate fluid intake because dehydration can develop. Visual changes can impair night driving; avoid hazardous activity when vision is affected. New breathing difficulty or marked cardiovascular symptoms needs prompt assessment.
Define trial success
Choose a functional target such as easier speech, safer swallowing of dry food, fewer nighttime awakenings, or improved oral comfort. Reassess response, sweating, hydration, hemodynamics, vision, breathing, and adherence rather than continuing an ineffective drug indefinitely.
Quick check
Checking for saved practice…
Lesson
Treat Active Organ Disease, Not Dryness by Default
Systemic treatment is organized around the affected organ, severity, reversibility, and risk. Topical care remains central for dryness, while glucocorticoids, conventional immunosuppressants, and biologics are reserved for selected systemic disease.
- ESSDAI
- Hydroxychloroquine
- Glucocorticoids
- Immunosuppressants
- Rituximab
Topical and secretory care remain the foundation for glandular symptoms.
Hydroxychloroquine, glucocorticoids, conventional therapy, and biologics have different roles.
Disease activity, function, infection, organ toxicity, and steroid burden define success.
Separate glandular and systemic goals
Artificial tears, oral prevention, and secretagogues treat glandular manifestations. Broad immunosuppression has not shown consistent value for dryness alone and should not substitute for surface protection.
Use hydroxychloroquine selectively
Hydroxychloroquine may be considered in selected inflammatory musculoskeletal or systemic contexts. It is not a dependable treatment for isolated dryness or fatigue, and standard retinal, interaction, and dose safety still apply.
Explain the limited-evidence HCQ option
BSR conditionally supports a six-to-twelve-month hydroxychloroquine trial for significant fatigue with systemic symptoms, and for significant hypergammaglobulinemia. Define measurable goals and reassess benefit. This limited-evidence option does not establish that hydroxychloroquine reliably relieves isolated dryness or nonspecific fatigue.
Use glucocorticoids cautiously
When active systemic disease requires glucocorticoids, use the minimum effective exposure and develop a taper or steroid sparing strategy. Infection, bone, metabolic, ocular, cardiovascular, and adrenal harms remain important.
Match immune therapy to the organ
Conventional immunosuppressants and biologics are selected for manifestations such as vasculitis, significant lung disease, renal disease, inflammatory neurologic disease, or hematologic complications. Evidence and choice differ across organs.
Distinguish neuropathy treatment pathways
The December 2025 Sjogren Foundation PNS guideline recommends prompt high-dose systemic glucocorticoids with rituximab when vasculitic neuropathy is strongly suspected. IVIG is not first-line therapy for that phenotype. By contrast, selected immune-mediated nonvasculitic neuropathies may warrant IVIG. Neuropathic pain can require gabapentin, pregabalin or an SNRI, but symptom relief does not replace treatment of nerve-threatening inflammation. Neurology and rheumatology coordinate evaluation and therapy.
Use biologics for selected severe disease
Rituximab and other targeted approaches are selected by organ phenotype and severity in specialist care. Some indications require early treatment rather than waiting for refractory disease. They are not routine therapy for uncomplicated sicca.
Quick check
Checking for saved practice…
Lesson
Build Lymphoma Surveillance Into Routine Care
Sjogren disease carries a clinically important lymphoma risk. Surveillance is not indiscriminate scanning; it is disciplined attention to gland, node, spleen, skin, constitutional, laboratory, and disease activity changes.
- Parotid enlargement
- Low C4
- Cryoglobulins
- Monoclonal gammopathy
- B symptoms
Persistent parotid enlargement, lymphadenopathy, splenomegaly, and purpura increase concern.
Low complement, cryoglobulins, cytopenias, and monoclonal patterns sharpen the signal.
Fever, drenching night sweats, and substantial weight loss need prompt evaluation.
Recognize clinical predictors
Persistent salivary gland enlargement, lymphadenopathy, splenomegaly, palpable purpura, peripheral neuropathy, and high systemic disease activity increase concern, especially when patterns change.
Recognize laboratory predictors
Low complement, cryoglobulinemia, lymphopenia or other cytopenias, hypergammaglobulinemia, rheumatoid factor, monoclonal gammopathy, and clonal lymphocytosis can strengthen concern in context.
Separate B symptoms from chronic fatigue
Unexplained fever, drenching night sweats, and substantial unintended weight loss are not routine fatigue. Infection, malignancy, and active systemic disease require evaluation.
Investigate the change
The workup is directed by the finding and may include examination, blood counts, chemistry, complement, protein studies, imaging, ultrasound, flow cytometry, or tissue diagnosis through rheumatology, hematology, radiology, and pathology.
Avoid false reassurance
Routine symptoms may fluctuate, but persistent unilateral gland enlargement, hard or fixed nodes, progressive cytopenia, or a new monoclonal pattern requires an explicit plan rather than watchful silence.
Quick check
Checking for saved practice…
Lesson
Coordinate Longitudinal Care and Pregnancy Before Risk Appears
Effective care connects rheumatology, ophthalmology, dental or oral medicine, primary care, pharmacy, and relevant organ specialists. Pregnancy, new organ symptoms, and treatment changes are planned rather than handled after complications emerge.
- Anti-SSA pregnancy
- Fetal surveillance
- Medication review
- Multidisciplinary care
- Reassessment
Rheumatology, eye, dental, primary, pharmacy, and organ specialists share one plan.
Anti-SSA and anti-SSB status changes medicine review and fetal surveillance.
Vision, intake, breathing, neurologic, glandular, constitutional, and toxicity changes trigger earlier care.
Plan pregnancy early
Anti-SSA with or without anti-SSB can cause neonatal lupus and fetal conduction disease. Preconception counseling aligns disease control, pregnancy compatible medicines, antibody status, and maternal fetal medicine involvement.
Use guideline based surveillance
ACR 2020 conditionally supports serial fetal echocardiography beginning at 16 to 18 weeks through week 26 in anti-SSA or anti-SSB positive pregnancy, less often than weekly when there is no prior infant with congenital heart block or other neonatal lupus; the exact interval is unspecified. After either prior outcome, ACR conditionally recommends weekly studies during that window. Its recommendation for hydroxychloroquine is also conditional unless contraindicated. Guidance differs: SMFM Consult 64 on SLE in pregnancy (2023, reaffirmed 2025) advises against routine serial PR-interval echocardiograms outside trials and routine steroids for antibody-associated fetal heart block. Discuss this disagreement with maternal-fetal medicine and fetal cardiology and document an individualized plan; do not present one surveillance schedule as universal consensus.
Review medicines as a system
Prescription, OTC, supplement, ocular, oral, and dental products all matter. Anticholinergic burden can worsen dryness, while immunotherapy, pregnancy, infection, organ function, and vaccine plans can alter safety.
Measure the disease domains
Follow symptom function, ocular staining and complications when indicated, dental injury, salivary function, nutrition, lung and neurologic symptoms, kidney and blood abnormalities, gland or node changes, and patient priorities.
Give a return plan
Earlier assessment is needed for vision change, severe eye pain, inability to eat or drink, new dyspnea, neurologic deficit, purpura, persistent gland swelling, fever, night sweats, weight loss, or medication toxicity.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 33 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- Sjogren Foundation PNS guideline: December 2025 recommendations, 2026 summary
- Yoshioka et al., Stability of Pilocarpine Ophthalmic Formulations (1986)
- BSR 2024 full guideline: institutional copy
- Sjogren Foundation: Oral caries prevention recommendations
- BSR 2024 guideline executive summary
- DailyMed: Restasis single-use prescribing information
- DailyMed: Cequa prescribing information
- SMFM Consult Series 64: antibody-associated fetal heart block and surveillance, 2023, reaffirmed 2025
- British Society for Rheumatology Guideline on Sjogren Disease, 2024
- EULAR Recommendations for Sjogren Syndrome Management
- 2016 ACR EULAR Classification Criteria
- Sjogren's Foundation Clinical Practice Guidelines
- ACR Reproductive Health Guideline
- DailyMed, Pilocarpine Hydrochloride
- DailyMed, Cevimeline Hydrochloride
- DailyMed, Lifitegrast Ophthalmic Solution